SurVaxM

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameSurVaxM
Drug Alias NameSurvivin-targeted peptide vaccineSurvivin peptide mimic vaccineSVN53-67/M57-KLH peptide vaccine
ClassificationVaccines > Development/production technology > Synthetic peptide vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)Neuroendocrine Carcinoma of LungSolid tumours +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesRoswell Park Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesRoswell Park Cancer InstituteNational Cancer InstituteMimivax LLC +[4] 
Inactive CompaniesN/A
Active IndicationsPancreatic neuroendocrine tumors (pNET)Neuroendocrine Carcinoma of LungSolid tumours +[15] 
Inactive IndicationsBrain NeoplasmsGlioma

Other Information

ATC CodeN/A
Related LinksN/A